Base de dados : MEDLINE
Pesquisa : C08.460.261 [Categoria DeCS]
Referências encontradas : 3913 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 392 ir para página                         

  1 / 3913 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280691
[Au] Autor:INTEGRATE (The National ENT Trainee Research Network); National ENT Trainee Research Network
[Ti] Título:The British Rhinological Society multidisciplinary consensus recommendations on the hospital management of epistaxis.
[So] Source:J Laryngol Otol;131(12):1142-1156, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Epistaxis is a common ENT emergency in the UK; however, despite the high incidence, there are currently no nationally accepted guidelines for its management. This paper seeks to recommend evidence-based best practice for the hospital management of epistaxis in adults. METHODS: Recommendations were developed using an Appraisal of Guidelines for Research and Evaluation ('AGREE II') framework. A multifaceted systematic review of the relevant literature was performed and a multidisciplinary consensus event held. Management recommendations were generated that linked the level of supporting evidence and a Grading of Recommendations Assessment, Development and Evaluation ('GRADE') score explaining the strength of recommendation. RECOMMENDATIONS: Despite a paucity of high-level evidence, management recommendations were formed across five management domains (initial assessment, cautery, intranasal agents, haematological factors, and surgery and radiological intervention). CONCLUSION: These consensus recommendations combine a wide-ranging review of the relevant literature with established and rigorous methods of guideline generation. Given the lack of high-level evidence supporting the recommendations, an element of caution should be used when implementing these findings.
[Mh] Termos MeSH primário: Epistaxe/terapia
Hospitalização
Comunicação Interdisciplinar
Colaboração Intersetorial
Otolaringologia
Equipe de Assistência ao Paciente
Sociedades Médicas
[Mh] Termos MeSH secundário: Medicina Baseada em Evidências
Auditoria Médica
Garantia da Qualidade dos Cuidados de Saúde
Reino Unido
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002018


  2 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280693
[Au] Autor:INTEGRATE (The National ENT Trainee Research Network); National ENT Trainee Research Network
[Ti] Título:Epistaxis 2016: national audit of management.
[So] Source:J Laryngol Otol;131(12):1131-1141, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Epistaxis is a common condition that can be associated with significant morbidity, and it places a considerable burden on our healthcare system. This national audit of management sought to assess current practice against newly created consensus recommendations and to expand our current evidence base. METHODS: The management of epistaxis patients who met the inclusion criteria, at 113 registered sites across the UK, was compared with audit standards during a 30-day window. Data were further utilised for explorative analysis. RESULTS: Data for 1826 cases were uploaded to the database, representing 94 per cent of all cases that met the inclusion criteria at participating sites. Sixty-two per cent of patients were successfully treated by ENT clinicians within 24 hours. The 30-day recurrent presentation rate across the dataset was 13.9 per cent. Significant event analysis revealed an all-cause 30-day mortality rate of 3.4 per cent. CONCLUSION: Audit findings demonstrate a varying alignment with consensus guidance, with explorative analysis countering some previously well-established tenets of management.
[Mh] Termos MeSH primário: Epistaxe/terapia
Auditoria Médica
[Mh] Termos MeSH secundário: Adulto
Epistaxe/mortalidade
Medicina Baseada em Evidências
Seres Humanos
Recidiva
Taxa de Sobrevida
Resultado do Tratamento
Reino Unido
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180124
[Lr] Data última revisão:
180124
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S002221511700202X


  3 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29224751
[Au] Autor:Shay S; Shapiro NL; Bhattacharyya N
[Ad] Endereço:Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 200 Medical Plaza, Suite 550, Los Angeles, CA 90095, USA. Electronic address: sshay@luriechildrens.org.
[Ti] Título:Epidemiological characteristics of pediatric epistaxis presenting to the emergency department.
[So] Source:Int J Pediatr Otorhinolaryngol;103:121-124, 2017 Dec.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Investigate the epidemiological characteristics of pediatric epistaxis in the emergency department setting. STUDY DESIGN: Cross-sectional study using national databases. METHODS: Children (age <18 years) presenting with a diagnosis of epistaxis were extracted from the State Emergency Department Databases for New York, Florida, Iowa, and California for the calendar year 2010. Associated diagnoses, procedures, encounter characteristics, and demographic data were examined. RESULTS: There were 18,745 cases of pediatric epistaxis (mean age 7.54 years, 57.4% male). Overall, 6.9% of patients underwent procedures to control epistaxis, of which 93.5% had simple anterior epistaxis control. The distribution of pediatric epistaxis was highest in spring and summer months (p < 0.001). Children from the lowest income quartile comprised a higher proportion of epistaxis presentations (38.8%, p < 0.001), yet were least likely to have an epistaxis control procedure performed (p < 0.001). Most patients had either Medicaid (43.8%) or private insurance (41.3%). Patients with Medicaid and those without healthcare coverage were least likely to undergo an epistaxis control procedure (p < 0.001). White children were more likely to undergo an epistaxis control procedure compared to those of minority backgrounds (p < 0.001). CONCLUSIONS: Most emergency department presentations of pediatric epistaxis are uninvolved cases that do not require procedural intervention. The overrepresentation of low socioeconomic status patients may suggest an overutilization of emergency services for minor cases of epistaxis, and perhaps a lack of access to primary care providers. This is the first study to evaluate racial and socioeconomic factors in relationship to pediatric epistaxis. Further investigation is needed to better elucidate these potential disparities.
[Mh] Termos MeSH primário: Serviço Hospitalar de Emergência/estatística & dados numéricos
Epistaxe/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Estudos Transversais
Bases de Dados Factuais
Feminino
Seres Humanos
Lactente
Masculino
Pediatria
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  4 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280698
[Au] Autor:Williams A; Biffen A; Pilkington N; Arrick L; Williams RJ; Smith ME; Smith M; Birchall J
[Ad] Endereço:Department of Anaesthesia,Derriford Hospital,Plymouth,UK.
[Ti] Título:Haematological factors in the management of adult epistaxis: systematic review.
[So] Source:J Laryngol Otol;131(12):1093-1107, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The management of epistaxis requires an understanding of haematological factors that may complicate its treatment. This systematic review includes six distinct reviews examining the evidence supporting epistaxis-specific management strategies relating to warfarin, direct oral anticoagulants, heparin, antiplatelet agents, tranexamic acid and transfusion. METHOD: A systematic review of the literature was performed using a standardised methodology and search strategy. RESULTS: Limited numbers of articles were identified in each systematic review, with level 1 evidence only regarding the use of tranexamic acid. No studies met the inclusion criteria within the heparin, direct oral anticoagulants or transfusion systematic reviews. Many studies were limited by small sample sizes and significant risk of bias. CONCLUSION: The management of major bleeding and transfusion practice is well documented in national guidance from multiple sources. The guidelines include advice on anticoagulants, antiplatelet agents and tranexamic acid. In the absence of more specific evidence, these guidelines should be applied in the management of epistaxis.
[Mh] Termos MeSH primário: Epistaxe/sangue
Epistaxe/terapia
[Mh] Termos MeSH secundário: Adulto
Anticoagulantes/efeitos adversos
Anticoagulantes/uso terapêutico
Transfusão de Sangue
Epistaxe/induzido quimicamente
Medicina Baseada em Evidências
Fidelidade a Diretrizes
Heparina/efeitos adversos
Heparina/uso terapêutico
Seres Humanos
Coeficiente Internacional Normatizado
Tempo de Internação
Inibidores da Agregação de Plaquetas/efeitos adversos
Inibidores da Agregação de Plaquetas/uso terapêutico
Ácido Tranexâmico/efeitos adversos
Ácido Tranexâmico/uso terapêutico
Resultado do Tratamento
Varfarina/efeitos adversos
Varfarina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Platelet Aggregation Inhibitors); 5Q7ZVV76EI (Warfarin); 6T84R30KC1 (Tranexamic Acid); 9005-49-6 (Heparin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002067


  5 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280696
[Au] Autor:Swords C; Patel A; Smith ME; Williams RJ; Kuhn I; Hopkins C
[Ad] Endereço:Department of Otolaryngology,Addenbrooke's Hospital,Cambridge,UK.
[Ti] Título:Surgical and interventional radiological management of adult epistaxis: systematic review.
[So] Source:J Laryngol Otol;131(12):1108-1130, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is variation regarding the use of surgery and interventional radiological techniques in the management of epistaxis. This review evaluates the effectiveness of surgical artery ligation compared to direct treatments (nasal packing, cautery), and that of embolisation compared to direct treatments and surgery. METHOD: A systematic review of the literature was performed using a standardised published methodology and custom database search strategy. RESULTS: Thirty-seven studies were identified relating to surgery, and 34 articles relating to interventional radiology. For patients with refractory epistaxis, endoscopic sphenopalatine artery ligation had the most favourable adverse effect profile and success rate compared to other forms of surgical artery ligation. Endoscopic sphenopalatine artery ligation and embolisation had similar success rates (73-100 per cent and 75-92 per cent, respectively), although embolisation was associated with more serious adverse effects (risk of stroke, 1.1-1.5 per cent). No articles directly compared the two techniques. CONCLUSION: Trials comparing endoscopic sphenopalatine artery ligation to embolisation are required to better evaluate the clinical and economic effects of intervention in epistaxis.
[Mh] Termos MeSH primário: Artérias/cirurgia
Cauterização/métodos
Embolização Terapêutica/métodos
Epistaxe/terapia
Ligadura/métodos
Nariz/irrigação sanguínea
Radiologia Intervencionista/métodos
[Mh] Termos MeSH secundário: Adulto
Cauterização/efeitos adversos
Embolização Terapêutica/efeitos adversos
Seres Humanos
Ligadura/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002079


  6 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280695
[Au] Autor:Iqbal IZ; Jones GH; Dawe N; Mamais C; Smith ME; Williams RJ; Kuhn I; Carrie S
[Ad] Endereço:Department of Otolaryngology,Freeman Hospital,Newcastle upon Tyne,UK.
[Ti] Título:Intranasal packs and haemostatic agents for the management of adult epistaxis: systematic review.
[So] Source:J Laryngol Otol;131(12):1065-1092, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The mainstay of management of epistaxis refractory to first aid and cautery is intranasal packing. This review aimed to identify evidence surrounding nasal pack use. METHOD: A systematic review of the literature was performed using standardised methodology. RESULTS: Twenty-seven eligible articles were identified relating to non-dissolvable packs and nine to dissolvable packs. Nasal packing appears to be more effective when applied by trained professionals. For non-dissolvable packs, the re-bleed rates for Rapid Rhino and Merocel were similar, but were higher with bismuth iodoform paraffin paste packing. Rapid Rhino packs were the most tolerated non-dissolvable packs. Evidence indicates that 96 per cent of re-bleeding occurs within the first 4 hours after nasal pack removal. Limited evidence suggests that dissolvable packs are effective and well tolerated by patients. There was a lack of evidence relating to: the duration of pack use, the economic effects of pack choice and the appropriate care setting for non-dissolvable packs. CONCLUSION: Rapid Rhino packs are the best tolerated, with efficacy equivalent to nasal tampons. FloSeal is easy to use, causes less discomfort and may be superior to Merocel in anterior epistaxis cases. There is no strong evidence to support prophylactic antibiotic use.
[Mh] Termos MeSH primário: Epistaxe/terapia
Hemostáticos/uso terapêutico
Tampões Cirúrgicos
[Mh] Termos MeSH secundário: Adulto
Terapia Combinada
Eletrocoagulação
Primeiros Socorros
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hemostatics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002055


  7 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280694
[Au] Autor:Khan M; Conroy K; Ubayasiri K; Constable J; Smith ME; Williams RJ; Kuhn I; Smith M; Philpott C
[Ad] Endereço:Department of Otolaryngology,Central Manchester University Hospitals,UK.
[Ti] Título:Initial assessment in the management of adult epistaxis: systematic review.
[So] Source:J Laryngol Otol;131(12):1035-1055, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The initial assessment of epistaxis patients commonly includes: first aid measures, observations, focused history taking, and clinical examinations and investigations. This systematic review aimed to identify evidence that informs how the initial assessment of these patients should be conducted. METHOD: A systematic review of the literature was performed using a standardised methodology and search strategy. RESULTS: Seventeen articles were included. Factors identified were: co-morbidity, intrinsic patient factors, coagulation screening and ice pack use. Hypertension and anticoagulant use were demonstrated to adversely affect outcomes. Coagulation screening is useful in patients on anticoagulant medication. Four studies could not be accessed. Retrospective methodology and insufficient statistical analysis limit several studies. CONCLUSION: Sustained ambulatory hypertension, anticoagulant therapy and posterior bleeding may be associated with recurrent epistaxis, and should be recorded. Oral ice pack use may decrease severity and can be considered as first aid. Coagulation studies are appropriate for patients with a history of anticoagulant use or bleeding diatheses.
[Mh] Termos MeSH primário: Epistaxe/etiologia
Epistaxe/terapia
[Mh] Termos MeSH secundário: Adulto
Comorbidade
Testes Diagnósticos de Rotina
Medicina Baseada em Evidências
Primeiros Socorros
Seres Humanos
Escala de Gravidade do Ferimento
Anamnese
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002031


  8 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280692
[Au] Autor:Mcleod RWJ; Price A; Williams RJ; Smith ME; Smith M; Owens D
[Ad] Endereço:ENT Department,University Hospital of Wales,Cardiff,UK.
[Ti] Título:Intranasal cautery for the management of adult epistaxis: systematic review.
[So] Source:J Laryngol Otol;131(12):1056-1064, 2017 Dec.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cauterisation techniques are commonly used and widely accepted for the management of epistaxis. This review assesses which methods of intranasal cautery should be endorsed as optimum treatment on the basis of benefits, risks, patient tolerance and economic assessment. METHOD: A systematic review of the literature was performed using a standardised methodology and search strategy. RESULTS: Eight studies were identified: seven prospective controlled trials and one randomised controlled trial. Pooling of data was possible from 3 studies, yielding a total of 830 patients. Significantly lower re-bleed rates were identified (p < 0.01) using electrocautery (14.5 per cent) when compared to chemical cautery (35.1 per cent). No evidence suggested that electrocautery was associated with more adverse events or discomfort. Limited evidence supported the use of a vasoconstrictor agent and operating microscope during the procedure. The included studies had considerable heterogeneity in terms of design and outcome measures. CONCLUSION: Consistent evidence suggests that electrocautery has higher success rates than chemical cautery, and is not associated with increased complications or patient discomfort. Lower quality evidence suggests that electrocautery reduces costs and duration of hospital stay.
[Mh] Termos MeSH primário: Cauterização/métodos
Endoscopia/métodos
Epistaxe/cirurgia
[Mh] Termos MeSH secundário: Adulto
Cauterização/economia
Eletrocoagulação/economia
Eletrocoagulação/métodos
Endoscopia/economia
Epistaxe/economia
Seres Humanos
Avaliação de Processos e Resultados (Cuidados de Saúde)/economia
Admissão do Paciente/economia
Recidiva
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117002043


  9 / 3913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742425
[Au] Autor:Min HJ; Kang H; Choi GJ; Kim KS
[Ad] Endereço:1 Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
[Ti] Título:Association between Hypertension and Epistaxis: Systematic Review and Meta-analysis.
[So] Source:Otolaryngol Head Neck Surg;157(6):921-927, 2017 Dec.
[Is] ISSN:1097-6817
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objective Whether there is an association or a cause-and-effect relationship between epistaxis and hypertension is a subject of longstanding controversy. The objective of this systematic review and meta-analysis was to determine the association between epistaxis and hypertension and to verify whether hypertension is an independent risk factor of epistaxis. Data Sources A comprehensive search was performed using the MEDLINE, EMBASE, and Cochrane Library databases. Review Methods The review was performed according to the Meta-analysis of Observational Studies in Epidemiology guidelines and reported using the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. Results We screened 2768 unique studies and selected 10 for this meta-analysis. Overall, the risk of epistaxis was significantly increased for patients with hypertension (odds ratio, 1.532 [95% confidence interval (CI), 1.181-1.986]; number needed to treat, 14.9 [95% CI, 12.3-19.0]). Results of the Q test and I statistics suggested considerable heterogeneity ([Formula: see text] = 0.038, I = 49.3%). The sensitivity analysis was performed by excluding 1 study at a time, and it revealed no change in statistical significance. Conclusion Although this meta-analysis had some limitations, our study demonstrated that hypertension was significantly associated with the risk of epistaxis. However, since this association does not support a causal relationship between hypertension and epistaxis, further clinical trials with large patient populations will be required to determine the impact of hypertension on epistaxis.
[Mh] Termos MeSH primário: Epistaxe/etiologia
Hipertensão/complicações
[Mh] Termos MeSH secundário: Seres Humanos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1177/0194599817721445


  10 / 3913 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28950288
[Au] Autor:Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
[Ad] Endereço:Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.
[Ti] Título:SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
[So] Source:Br J Cancer;117(7):938-946, 2017 Sep 26.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell lung cancer. METHODS: In this Phase I, open-label study (NCT01809210), treatment-naïve patients received selumetinib (50, 75, 100 mg BID PO) plus standard doses of gemcitabine or pemetrexed plus cisplatin or carboplatin. Primary objectives were safety, tolerability, and determination of recommended Phase II doses. RESULTS: Fifty-five patients received treatment: selumetinib 50 or 75 mg plus gemcitabine/cisplatin (n=10); selumetinib 50 mg plus gemcitabine/carboplatin (n=9); selumetinib 50, 75 or 100 mg plus pemetrexed/carboplatin (n=21); selumetinib 75 mg plus pemetrexed/cisplatin (n=15). Most frequent adverse events (AEs) were fatigue, nausea, diarrhoea and vomiting. Grade ⩾3 selumetinib-related AEs were reported in 30 (55%) patients. Dose-limiting toxicities (all n=1) were Grade 4 anaemia (selumetinib 75 mg plus gemcitabine/cisplatin), Grade 4 thrombocytopenia/epistaxis and Grade 4 thrombocytopenia (selumetinib 50 mg plus gemcitabine/carboplatin), Grade 4 febrile neutropenia (selumetinib 100 mg plus pemetrexed/carboplatin), and Grade 3 lethargy (selumetinib 75 mg plus pemetrexed/cisplatin). Partial responses were confirmed in 11 (20%) and unconfirmed in 9 (16%) patients. CONCLUSIONS: Standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin were tolerated with selumetinib 75 mg BID. The selumetinib plus gemcitabine-containing regimens were not tolerated.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Anemia/induzido quimicamente
Benzimidazóis/administração & dosagem
Benzimidazóis/efeitos adversos
Carboplatina/administração & dosagem
Neutropenia Febril Induzida por Quimioterapia/etiologia
Cisplatino/administração & dosagem
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Diarreia/induzido quimicamente
Epistaxe/induzido quimicamente
Fadiga/induzido quimicamente
Feminino
Seres Humanos
Letargia/induzido quimicamente
Masculino
Meia-Idade
Náusea/induzido quimicamente
Pemetrexede/administração & dosagem
Inibidores de Proteínas Quinases/administração & dosagem
Inibidores de Proteínas Quinases/efeitos adversos
Trombocitopenia/induzido quimicamente
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (AZD 6244); 0 (Benzimidazoles); 0 (Protein Kinase Inhibitors); 04Q9AIZ7NO (Pemetrexed); 0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine); BG3F62OND5 (Carboplatin); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.271



página 1 de 392 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde